Grail rises as $110 mln Samsung-backed funding boosts cancer test expansion

Grail

25/06/2026 14:12

** Shares of Grail GRAL.O rise 6.2% to $68.58 premarket
** The cancer test maker says it raised $110 mln via equity sale to Samsung affiliates to support growth and global expansion
** Adds that investment was priced at $70.05 per share
** Notes partnership with Samsung C&T aims to bring Galleri cancer screening test to South Korea and potentially to Japan and Singapore
** Galleri screens for over 50 cancers, including some without routine tests, company said
** Testing initially to be done in North Carolina lab - GRAL
** Test not approved by U.S. FDA and does not detect all cancers, GRAIL adds
** As of last close, stock down ~25% YTD   
 
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))